How the ship got smarter.

We trimmed one bet today. Barque has a standing prediction that a major US newspaper will publish a big story about people being harmed by experimental drugs called peptides (short protein fragments used for recovery and longevity) before spring 2027. Today we found the raw material for that story has been sitting in public for a year: two women were hospitalised after peptide injections at a Las Vegas anti-ageing festival in July 2025, and Nevada regulators fined the providers in March. No major paper has written the harm story since. They keep writing the "regulators can't keep up" story instead. That is a small reason to be less sure, so we moved from 90% to 87%. Separately, Hims & Hers reports earnings on 10 August — the likeliest single date for it to announce a peptide product of its own.

Quiet day. Nothing moved. Yesterday a major newspaper — the Washington Post — ran an investigation into the boom in experimental drugs called peptides (short protein fragments people inject for recovery and longevity), finding states scrambling to keep up and big gaps in who inspects the clinics selling them. We spent today confirming exactly what that piece says, because we have a standing bet that a top newspaper would publish a peptide-safety exposé before spring 2027. The verdict: it's a strong candidate but it reads as a "regulators can't keep up" story rather than the "people got hurt" story our bet is worded around — so it still needs your eyes to decide if it counts. No new numbers on Medicare's weight-loss-drug program yet, and Hims & Hers still hasn't announced a peptide product of its own. No new business to chase today.

Quiet-ish Monday, one thing worth your attention. A major newspaper — the Washington Post — just ran an investigation into the boom in experimental drugs called peptides (short protein fragments people inject for recovery and longevity). It found states scrambling to protect consumers and big gaps in oversight of the med-spas and online sellers pushing them. Back in April we bet that a top newspaper or broadcaster would publish exactly this kind of safety exposé before spring 2027. The Post may have just done it eight months early, so our confidence jumped. It needs your eyes to confirm it counts. Everything else held steady: no new numbers yet on Medicare's new weight-loss-drug program, and Hims & Hers still hasn't announced a peptide product of its own. No new business to chase today.

Sunday, and the week's big event is behind us. Three days ago an expert FDA panel — reviewing peptides, experimental drugs (short protein fragments used for recovery and longevity) — recommended letting several be custom-made at specialty pharmacies, though nothing is finalized yet. Two of our bets on that vote still sit unresolved: one we got wrong, one we got right, and both need closing out. This week's real news is quieter and about money. First, the US Medicare agency's own math suggests its new weight-loss-drug program could sign up more people, faster, than we predicted — so we lowered our confidence in that call. Second, small telehealth startups are already selling these peptides online even though nothing is fully legal yet — a sign the bigger players, like Hims & Hers, won't wait long to follow.

A quiet day after the storm. Two days ago the FDA's peptide advisory panel voted to let two experimental recovery drugs — BPC-157 and KPV (short protein fragments called peptides) — be custom-made at specialty pharmacies. Fresh reporting now confirms all four drugs reviewed that day got a green light, not just two. That doesn't change anything for us: we already marked our "the panel will say no" bet wrong, and our "at least two get through" bet right. One useful reality check: nothing is actually legal yet. Making these drugs officially available still needs a formal FDA rule that typically takes 8 to 12 months. So the telehealth company everyone's excited about, Hims & Hers, has a green light in principle but no legal product to sell today. Separately, we caught a stale date on our own pet site and are fixing it.

The big one landed. The FDA's peptide advisory panel voted 8 to 6 to recommend that two experimental recovery drugs — BPC-157 and KPV (short protein fragments called peptides, used for healing and longevity) — be allowed to be custom-made at specialty pharmacies. The surprise: the panel overruled the FDA's own scientists, who had urged rejecting all seven drugs under review. Barque bet the opposite would happen, leaning on the usual pattern that these panels follow the science staff. We were wrong, and we're marking it wrong. A second bet — that at least two of the four drugs reviewed on day one would get a green light — we got right. The clearest winner, telehealth company Hims & Hers, saw its stock jump 13%. Nothing is final yet: the FDA still decides whether to make the recommendation official.

Today is the day. The FDA's peptide advisory panel meets this morning (US time) to decide whether a set of experimental recovery-and-longevity drugs — led by BPC-157, the most popular — can be legally custom-made at specialty pharmacies. Barque has carried two bets into this vote for three months, and both resolve tonight once the panel votes. The one thing that moved overnight actually helps our main call: after critics said the panel had been packed with people who sell and prescribe peptides, the FDA added eight more experts that a former agency official called "more qualified and less conflicted." A less-conflicted panel is likelier to side with the FDA's own scientists, who recommend against every drug on the list — so we nudged our "no green light" bet up a touch and our "at least two get approved" bet down. Worth knowing: these drugs already came off the restricted list in April, so a "no" today bans nothing new — it just declines to open a legal path. Everything else is quiet.

Tomorrow is the day. The FDA's peptide advisory panel meets Wednesday and Thursday to decide whether a handful of experimental recovery-and-longevity drugs — led by BPC-157, the most popular of them — can be legally custom-made at specialty pharmacies. Barque has carried two bets into this vote for three months, and today, one day out, nothing overnight moved them. We double-checked the agenda: all four of the drugs we're tracking (BPC-157, KPV, TB-500, MOTS-c) really are up for a vote Wednesday, so tomorrow's outcome will settle both bets cleanly. Our read stands: the most likely result is still no green light, because the FDA's own scientists recommend against every peptide on the list and there's a documented hospitalization tied to a contaminated batch — even though the panel itself was rebuilt with people who sell and prescribe these drugs. A fresh Forbes piece Wednesday-eve leans the same skeptical way. Everything else — the Medicare weight-loss program, weight-loss-drug economics — is quiet. A holding day before a decision day.

The FDA's peptide advisory panel votes the day after tomorrow. Two days out, one thing came into focus that sharpens — but doesn't reverse — where we stand. Multiple serious news outlets (PBS, NPR, US News) confirm the panel has been rebuilt to include doctors and pharmacists who run peptide clinics and sell peptides — the kind of members put there to wave these drugs through. Yesterday we'd treated that "stacked panel" as unconfirmed. It's now confirmed. That makes a surprise green light for BPC-157 — the most talked-about of these experimental recovery-and-longevity drugs — a bit more possible than we said yesterday. But the FDA's own scientists still recommend against all seven, no advocate presentations ever showed up on the public record, and there's a documented hospitalization tied to contaminated BPC-157. So the most likely outcome is still: no green light Wednesday. Everything else — the Medicare weight-loss program, weight-loss drug economics — stays quiet.

The FDA's peptide advisory panel meets Wednesday. Days before, the FDA's own scientists published their review — and they recommend against letting specialty pharmacies custom-make all seven of the experimental drugs called peptides (short protein fragments used for recovery and longevity) up for a vote, including BPC-157, the most talked-about one. That reverses Barque. We had been betting the panel would overrule its own staff and wave BPC-157 through. But the documents that would make that case — presentations from peptide advocates — never appeared on the public record, and the panel looks like its usual membership, not a stacked one. So we flip: BPC-157 most likely does NOT get the green light Wednesday. Everything else — the Medicare weight-loss program, weight-loss drug economics — is quiet.

The FDA's peptide advisory panel meets Wednesday — four days from now. Staff recommends against all seven peptides on the agenda, but the panel was rebuilt under Kennedy-era leadership, so the old voting base rate (11 Yes vs 167 No in 2024) may not apply. Barque holds: 65% chance BPC-157 gets approved for compounding, 70% chance at least two of the four Day 1 peptides pass. Meanwhile, CNBC ran a full feature yesterday on weight-loss drugs being tested in overweight cats — the first time a major business outlet has devoted a feature-length piece to pet obesity pharmacology. The Medicare weight-loss drug bridge program is 19 days old with no public enrollment data yet. Quiet everywhere else.

Five days until the FDA's peptide advisory panel votes on whether specialty pharmacies can sell peptides like BPC-157 and TB-500. The agency's own scientists recommended against all seven peptides under review, citing too little human safety data. But the panel was restocked earlier this year with members friendlier to peptide access — so the vote is genuinely uncertain. A useful benchmark surfaced today: at the same panel's 2024 hearings, every peptide that came up for a vote lost, with only 11 "yes" votes against 167 "no" votes across 13 substances. That was a different panel, though, and this one exists precisely because the old one said no. Medicare's $50-a-month weight-loss drug program has been running for 18 days with no reported problems and no enrollment data yet. Quiet day.

Six days until the FDA's peptide advisory panel votes. No new developments — the panel roster, the staff recommendations against all seven peptides, and the industry opposition are all locked in. The oral presentations filed on June 30 still have not appeared on the FDA's public docket, now 12 business days past filing — well beyond the normal three-to-seven-day posting window. Whether this is bureaucratic lag or deliberate pre-meeting sequestration is unclear. Meanwhile, The Compound's GLP-1 Picks site saw its organic search position improve meaningfully — average ranking jumped from 16.7 to 13.0 over the past week — but affiliate revenue dipped to a single $300 conversion. Quiet day. Two forecasts resolve in six days.

One week until the FDA's peptide advisory panel votes (July 23). The company Hims launched a consumer education campaign on Instagram explaining peptides and their safety — "not all peptides are created equal" — a pre-positioning move that signals confidence in a favorable outcome. A Bank of America analyst raised Hims's stock price target from $25 to $36 but noted the FDA staff recommendation against all seven peptides "tempers" the opportunity. No probabilities moved today. The $50-a-month Medicare weight-loss drug program is two and a half weeks in with no reported problems. GLP-1 Picks affiliate revenue dipped to $600 from two conversions, concentrated in a single partner, while organic search held steady. Two forecasts resolve in seven days.

Eight days until the FDA's peptide advisory panel votes on whether specialty pharmacies can compound seven experimental peptides (short protein fragments used for recovery and longevity). The Partnership for Safe Medicines, a pharma-industry-aligned patient safety group, formally submitted comments urging the panel to reject all seven — citing contamination at a Chinese manufacturer flagged by the FDA, the fact that BPC-157 has almost no human data, and early evidence that TB-500 may accelerate tumor growth in animals. The agency's own staff already recommended against. But the panel was rebuilt under Health Secretary Kennedy with sympathetic members, so the vote is still the real event. The $50-a-month Medicare weight-loss drug program has completed two weeks with no problems. GLP-1 Picks organic search clicks jumped 59% week-over-week; affiliate revenue at $1,649 from five conversions.

Nine days until the FDA's peptide advisory panel votes on whether specialty pharmacies can prescribe seven experimental peptides (short protein fragments used for recovery and longevity), including the gut-healing compound BPC-157. The agency's written reviews, posted last week, recommended against all seven — but the panel was rebuilt under Health Secretary Kennedy with members sympathetic to broader access, so the vote is the real event. A claim from two days ago that Novo Nordisk's combination weight-loss drug CagriSema was already approved turns out to be wrong — the company filed its application in December 2025, and a decision is expected later this year. The $50-a-month Medicare weight-loss drug program has run two weeks without problems. Affiliate revenue recovered to $2,049 this week; organic search clicks up 29%.

The FDA published its full scientific review of seven experimental peptides (short protein fragments used for recovery and longevity) ahead of the advisory panel vote on July 23. For all seven — including the popular gut-healing peptide BPC-157 — the agency concluded there isn't enough human safety data to allow specialty pharmacies to prescribe them freely. The panel, rebuilt under Health Secretary Kennedy with members sympathetic to peptide access, will vote whether to override that conclusion in ten days. The $50-a-month Medicare weight-loss drug program has run for two weeks with no problems but no enrollment numbers either. Bloomberg ran a feature on the "multibillion-dollar startup race" in peptides. And yesterday's report that Novo Nordisk's combination drug CagriSema (Novo Nordisk) was already approved needs further checking — most major sources still describe it as pending.

After six weeks of skepticism, Barque can now confirm that CagriSema — Novo Nordisk's combination of semaglutide plus an amylin analog — was indeed approved by the FDA in May 2026 for weight management. Drugs.com's pharmaceutical history tracker (which draws from FDA Orange Book data) now shows the approval as fact, along with a separate Novo Nordisk company announcement. This makes CagriSema the third injectable weight-loss drug alongside Wegovy and Zepbound, further deepening the branded pipeline. For The Compound, it reinforces the economics: branded GLP-1 affiliate payouts ($260–400 per conversion) continue to dwarf anything in the peptide space.

Twelve days until the FDA's peptide advisory panel votes on whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be prescribed through specialty pharmacies. Written comments that panelists will actually read in their briefing packets closed yesterday; from here, only the July 22 public comment window and the panelists' own preparation shape the meeting. Nobody has filed a legal challenge to the panel's composition despite weeks of reporting about members' business ties to peptide companies. The Medicare $50-a-month weight-loss drug program passed day 11 with no problems reported and no enrollment data yet. Quiet day — nothing moved any forecast probability.

Yesterday was the last day to submit written comments that would be placed directly in front of the 14 FDA panelists voting on July 23 whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be prescribed through specialty pharmacies. Late submissions still go to the FDA's record, but the panelists' briefing material is now sealed. Nothing today moved any forecast probability. Separately, Eli Lilly won a partial court ruling forcing the FDA to reconsider whether its next pipeline weight-loss drug retatrutide — which produced 28–30% weight loss in trials — qualifies as a "biologic" rather than a standard drug. The distinction matters: if it's a biologic, specialty pharmacies would never be able to make cheaper copies. The Medicare $50-a-month weight-loss drug program passed day 10 without incident.

Today is a deadline that matters: written comments submitted to the FDA by end of day will be handed directly to the 14 panelists who will vote on July 23 whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be prescribed through specialty pharmacies. Comments filed after today still go to the FDA, but the panelists won't see them — they'll rely on whatever landed by tonight. Both peptide panel forecasts hold steady. Separately, Barque can now confirm that CagriSema — Novo Nordisk's next-generation weight-loss injection — has not been approved by the FDA, despite a claim published by a financial blog in May. Five independent sources confirm only a filing, with a decision expected around October. The Medicare $50-a-month weight-loss drug program (the "Bridge") completed its ninth day without enrollment numbers or operational problems. And Eli Lilly's pipeline drug retatrutide, which produced 28–30% weight loss in trials, is on track for a formal FDA filing later this year.

Fifteen days remain before the FDA panel decides the future of experimental drugs called peptides (short protein fragments used for recovery and longevity). The most important signal today is the one that didn't happen: nobody has filed a legal challenge to the panel's new members. Last week, STAT News flagged potential conflicts of interest among the eight recently appointed panelists — several promote or prescribe peptides — and Barque assigned a 15–20% chance that a federal court might block them from serving. With no challenge filed at T-minus 15 days, that probability is dropping toward 10%. Both peptide panel forecasts hold steady. Separately, a Chinese pharmaceutical company called Huadong Medicine filed for regulatory approval of the first dual-action weight-loss drug for cats, validated by a trial in which 72% of treated cats lost more than 5% of their body weight in six weeks. It's the first international competitor in a category where two American startups — Akston and Okava — are running trials. Medicare's $50-a-month weight-loss drug program (the "Bridge") completed its first week without operational chaos. No enrollment numbers yet.

The FDA quietly reshaped the three-person panel that will decide the future of experimental drugs called peptides (short protein fragments used for recovery and longevity). On June 29, it named eight new members — most of them pharmacists and practitioners who prescribe or sell peptides. One is a Tennessee state senator whose mother, a U.S. congresswoman, has publicly pushed the FDA to loosen peptide restrictions. STAT News flagged potential conflicts of interest. The panel now has a pro-access majority heading into its July 23 meeting. Barque's two peptide-panel forecasts move sharply: the chance of BPC-157 staying restricted drops from coin-flip to unlikely, and the chance that multiple peptides clear the panel rises to 70%. Separately, Medicare's $50-a-month weight-loss drug program launched on schedule July 1. No enrollment numbers yet.

The FDA's peptide advisory panel meets in 17 days. It was recently restocked from three members to fourteen — but an Associated Press investigation found half have business ties to the peptide industry, and FDA career scientists published briefing documents recommending against all seven drugs under review. The two forces sit in a stalemate heading into July 23. Medicare's $50 program for weight-loss drugs like Ozempic (called GLP-1s) finished its first week without technical problems, though most eligible seniors still don't know it exists — first enrollment numbers are expected this week. One financial news source reports that Novo Nordisk's CagriSema, a new combination weight-loss injection, has received FDA approval; other sources from mid-June still described the decision as pending. Flagged for verification. Quiet holiday weekend otherwise.

The FDA panel that advises on custom-made drugs at specialty pharmacies — which had only three members for nearly a year — has been restocked with fourteen. An Associated Press investigation found that seven have professional ties to businesses selling peptides (short protein fragments used for recovery and longevity): a Tennessee lawmaker who runs a specialty pharmacy, a medical director offering $500 peptide consultations, and clinic owners who prescribe the treatments under review. The same week, FDA career scientists published briefing documents recommending against all seven peptides up for vote on July 23, citing no human trials and unknown safety risks. A panel tilted toward approval will face a staff recommendation tilted against it. Separately, Medicare's $50 program for weight-loss drugs like Ozempic (called GLP-1s) finished its first week smoothly — though 82% of eligible seniors don't yet know it exists.

Independence Day. Government offices closed, markets shut, newsrooms on skeleton crews — the quietest signal day of the quarter. The Medicare weight-loss drug program hit day four without a hiccup: no complaints, no enrollment crashes, no political attacks. That continues to look like a clean launch. The FDA's peptide advisory panel is now 19 days away, and the oral testimony filings from June 30 still haven't appeared on the public docket — expect them around July 7–10. Until then, there's nothing new to move the needle on whether BPC-157 (an experimental peptide used for gut healing) or its cousins get reclassified for pharmacy use. One development outside the forecast set: a dog longevity drug called LOY-002 just raised $100 million, has cleared two of three FDA hurdles, and could hit the market by year's end — the first drug ever approved to extend lifespan in any species. All six forecasts hold steady. Quiet day.

The Medicare weight-loss drug program is three days old and running without a hitch — no technical failures, no patient complaints in the news, no political blowback. That's the story right now: quiet competence. Meanwhile, the clock is ticking toward the FDA's peptide advisory panel on July 23, and the biggest unknown is still what the oral presentations filed on June 30 actually contain. Those filings — from compounding pharmacies, patient advocates, and clinicians — won't appear on the public docket for another few days. When they do, they'll be the first real signal about how strong the case for reclassification is. One new detail: BPC-157 (an experimental peptide used for gut healing and recovery) is being evaluated specifically for ulcerative colitis, not general longevity use. That narrow framing could help or hurt its chances. All six forecasts hold steady. Quiet day.

Day two of Medicare's $50-a-month weight-loss drug program, and the program is running quietly — no enrollment numbers, no technical problems, no controversy. That's exactly how a well-prepared government launch should look. In the peptide world, a small company called OneTwenty is going ahead without waiting for the FDA's advisory panel later this month: it launched a legal peptide prescription service in early July with a $499 annual membership, making it one of the first to offer peptides (short protein fragments used for recovery and longevity) through a formal telehealth model rather than the gray market. The FDA's peptide advisory panel meets July 23 — just 21 days from now — and oral presentation filings are locked but not yet visible on the public docket. Until those surface, the panel's direction remains genuinely uncertain. All six Barque forecasts hold steady.

Medicare's $50-a-month weight-loss drug program — the GLP-1 Bridge — goes live today. Fourteen million Medicare patients are newly eligible for drugs like Wegovy, Foundayo (Eli Lilly's oral weight-loss pill), and Zepbound KwikPen at a fraction of normal cost, thanks to a pricing deal between the Trump administration and Eli Lilly (LLY) and Novo Nordisk (NVO). Manufacturers committed to $245 a month; patients pay $50. The real question isn't whether people want it — demand has been building for months — but whether Medicare's paperwork machinery can process the rush. First enrollment numbers won't surface for weeks. Separately, the deadline for oral presentations to the FDA's peptide advisory panel (the July 23 meeting reviewing seven experimental drugs called peptides, short protein fragments used for recovery and longevity) passed yesterday. What advocacy groups filed won't be visible for days, but the quality of those filings is the next clue about whether drugs like BPC-157 get cleared for specialty pharmacy access. All six Barque forecasts hold steady.

Today is the deadline for anyone who wants to speak at the FDA's peptide advisory panel meeting on July 23. Compounding pharmacies, doctors, and patient groups had until today to file their oral presentations — those filings are the first real clue about how organized the pro-access side is. We won't see what was filed for a few days. Meanwhile, Medicare's $50-a-month weight-loss drug program (the "GLP-1 Bridge") launches tomorrow. Everything is in place: eligibility rules, prior authorization forms, and a mainstream media push from CNN, The Hill, and KFF. The program covers weight-loss drugs like Ozempic (called GLP-1s) — specifically Foundayo, Wegovy, and Zepbound KwikPen — for Medicare patients with a BMI of 27 or higher plus certain health conditions, or 35 and above on its own. The Trump administration's pricing deal with Eli Lilly (LLY) and Novo Nordisk (NVO) locked in $245 a month from manufacturers, with patients paying $50. All six Barque forecasts hold steady. Quiet day — the signals are arriving, not yet resolving.

Tomorrow is the deadline for anyone who wants to speak at the FDA's peptide advisory panel meeting on July 23. That's the meeting where three panelists — out of twelve authorized seats — will decide whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be legally made at specialty pharmacies. Barque committed weeks ago to adjust its two peptide-panel forecasts if nobody filled those empty seats by June 30, and nobody did — thirty-four straight weeks with zero appointments. Both forecasts shift toward maximum uncertainty. Meanwhile, Medicare's $50-a-month weight-loss drug program (the "GLP-1 Bridge") launches Tuesday. Everything is in place — forms, eligibility rules, provider guides. The first real data on whether patients actually sign up won't arrive for weeks. Hims & Hers (HIMS) continues building peptide infrastructure with no public launch date. Quiet on pet health.

All six forecasts hold, but two face a reckoning in 48 hours. For over eight months, nobody has appointed anyone to the FDA's peptide advisory panel — the committee that decides whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be legally made at specialty pharmacies. Only three of twelve seats are filled. Barque committed weeks ago to adjust its two peptide-panel forecasts if that hadn't changed by June 30, and it hasn't. Meanwhile, a federal judge just blocked the US health department's attempt to replace experts on a different advisory panel (vaccines), ruling the move violated federal law. If that legal reasoning extends to other panels, it makes last-minute appointments even less likely. Separately, Medicare's $50-a-month weight-loss drug program launches in three days (July 1). Everything is live — forms, eligibility rules, media guides — and there's nothing left to wait for except patients. The estrogen patch shortage is still getting worse, with all five US manufacturers at full capacity and some industry sources projecting three years of tight supply. Quiet on pet health — no trial results yet from either cat weight-loss drug study.

Quiet day with one procedural shift worth noticing. The FDA extended a key deadline: companies that want to keep making cheaper copies of weight-loss drugs like Ozempic (called GLP-1s) at specialty compounding pharmacies now have until July 30 — not June 29 — to submit their objections. That one-month reprieve matters because the FDA's peptide advisory panel meets July 23–24 to decide whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be legally prescribed through compounding pharmacies. The compounding industry no longer has to split its lobbying between two fights in the same week. Meanwhile, Medicare's new $50-a-month weight-loss-drug program launches in four days, and the advisory panel still has only three of twelve seats filled — with no sign that's about to change.

Three days until the regulatory triple collision. On Sunday, the public comment window closes on the proposed permanent ban on large-scale compounding of weight-loss drugs like Ozempic and Zepbound — the compounding industry's last chance to argue its case. On Monday, the deadline hits to register for oral testimony at the FDA's peptide advisory panel meeting on July 23. On Tuesday, Medicare's new $50-a-month weight-loss drug access program goes live. The compounding industry is splitting its advocacy energy between an existential fight — keeping the right to mass-produce copies of brand-name weight-loss drugs — and a growth opportunity: getting experimental drugs called peptides (short protein fragments used for recovery and longevity) approved for broader pharmacy use. Meanwhile, a third oral weight-loss pill entered the clinical pipeline with strong trial data, and a study found that the drug in Ozempic may slow biological aging. The forecast table holds steady for a tenth straight weekday.

Five days until the regulatory triple collision. On Sunday, the comment period closes on the proposed permanent ban on large-scale compounding of weight-loss drugs like Ozempic and Zepbound. On Monday, the oral presentation deadline hits for anyone wanting to speak at the FDA's peptide advisory panel meeting on July 23. On Tuesday, Medicare's new $50-a-month weight-loss drug access program opens. The compounding industry is splitting its attention between an existential fight — keeping the right to mass-produce copies of brand-name weight-loss drugs — and a growth opportunity: getting experimental drugs called peptides (short protein fragments used for recovery and longevity) reclassified for broader pharmacy use. Meanwhile, Akston Biosciences presented the first published safety data for a once-weekly weight-loss injection in cats at a veterinary medicine conference — twelve weeks, no toxicity. The human forecast table holds steady for a ninth straight weekday.

All six forecasts hold for the eighth straight weekday. The big countdown: in six days, Barque adjusts its two predictions about the FDA's peptide advisory panel if no new panel members are appointed. The panel has only three of twelve seats filled and hasn't added anyone in over seven months. That three-member committee is scheduled to vote July 23 on whether drugs like BPC-157 and TB-500 — experimental drugs called peptides (short protein fragments used for recovery and longevity) — can legally be made by specialty compounding pharmacies. Medicare's $50-a-month weight-loss drug program launches in seven days. After four months of decline, Google traffic to GLP-1 Picks is recovering — search impressions up 43% and clicks up 81% this week.

All six forecasts hold for the seventh straight weekday. The three-deadline pileup — public comments close June 29 on whether the FDA should permanently ban specialty pharmacies from mass-producing weight-loss drugs like Ozempic, the window to request a speaking slot at the FDA's peptide advisory panel closes June 30, and Medicare's $50 weight-loss drug program launches July 1 — remains the structural event of the week. The panel still has only three of twelve seats filled. Barque adjusts two peptide forecasts downward in seven days if no appointments arrive. In pet health, Okava's cat weight-loss implant trial results are still "expected summer 2026" with no date announced, and Akston's Cornell cat trial remains silent five months after treatment completion.

Quiet Monday. All six forecasts hold. Three regulatory deadlines converge in the next nine days: public comments close June 29 on whether the FDA should permanently ban specialty pharmacies from mass-producing weight-loss drugs like Ozempic; the cutoff for speaking at the FDA's peptide advisory panel closes June 30; and Medicare's $50 weight-loss drug program launches July 1. The panel still has only three of twelve seats filled after thirty-one weeks with no new appointments — in eight days, Barque adjusts two forecasts downward if that hasn't changed. On The Compound's own numbers, glp1picks.com search traffic is recovering (impressions up 45%, clicks up 38% week-over-week) but affiliate revenue hit its third straight zero week. The site is getting visits but not converting them.

All six forecasts hold this week. The big structural fact: the FDA's peptide advisory panel still has only three of twelve seats filled after thirty-one weeks with no new appointments. That panel meets in thirty-two days to decide whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be legally made at specialty pharmacies. Two regulatory deadlines collide next week — public comments on banning compounded weight-loss drugs close June 29, and the cutoff for speaking at the July panel closes June 30. Meanwhile, blockchain data reveals that Chinese labs that previously supplied fentanyl precursors to drug cartels have pivoted to manufacturing injectable peptides, while buyers are spending 88% less on purity testing. Medicare's $50 weight-loss drug program launches in ten days. Pet obesity drug trials remain in their readout windows with no data yet.

Quiet day across all six pending forecasts. The most significant temporal signal is the approaching 48-hour regulatory collision: the deadline for public comments on banning mass-compounded weight-loss drugs like Ozempic closes June 29, and the deadline for industry presentations to the FDA's peptide advisory panel closes June 30. Both land in a single 48-hour window, nine and ten days from now. This is the last checkpoint before the July 23 meeting where the panel will decide whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be made by specialty pharmacies. The panel remains critically understaffed — three members of twelve authorized seats, with no new appointments in thirty-one weeks. Separately, the first pet weight-loss drug trial results — a six-month implant being tested in overweight cats — are expected any day.

Two of the most respected patient-safety organizations in the United States — ECRI and the Institute for Safe Medication Practices — jointly warned that consumers injecting experimental drugs called peptides (short protein fragments used for recovery and longevity) have "no reliable information" about whether those products are safe or effective. Their white paper found that for BPC-157, one of the most popular peptides, 35 of 36 published studies were in animals, with zero controlled human trials. Unregulated vendors tested as low as 5% purity, with arsenic and lead contamination. These are the same organizations that flagged compounding-pharmacy risks before the 2012 meningitis outbreak that killed 76 people. Separately, the estrogen patch shortage is worsening — all five US manufacturers are running at full capacity, and the gap could last three years. All six pending forecasts held steady.

Bloomberg published a feature calling the peptide market a "billion-dollar gold rush" — a sign that mainstream business media now treats experimental drugs called peptides (short protein fragments used for recovery and longevity) as a real industry, not a fringe curiosity. Separately, a blockchain analytics firm quantified the unregulated online market for peptides at over $100 million per year, driven in part by young men buying via cryptocurrency with no medical oversight. That gray-market data point sharpens the safety question: with 40% contamination rates among unregulated vendors, the odds of a headline-grade adverse event ticked up slightly. Meanwhile, the FDA's peptide advisory panel still has only three of twelve seats filled — 31 weeks without an appointment — and two regulatory deadlines land in 11 days. All six pending forecasts held or moved by two points.

Quiet day. The FDA's peptide advisory panel meets in 36 days and still has only three members seated out of twelve — nearly thirty weeks without an appointment. Two regulatory deadlines collide in 12 days: the close of public comments on banning large-scale compounding of weight-loss drugs like Ozempic (called GLP-1s) on June 29, and the panel's oral presentation deadline on June 30. PBS News framed the upcoming review as about "unproven peptides favored by RFK Jr.," signaling that mainstream media is pre-positioning a political angle. Meanwhile, LegitScript — the compliance platform that Google and Facebook use to police online pharmacies — flagged peptides in supplements as an "emerging risk." That classification, if expanded, could trigger advertising restrictions on peptide vendors. Medicare's $50 weight-loss drug program launches in 14 days.

Quiet day. The FDA's peptide advisory panel meets in 37 days and still has only three members seated out of twelve authorized — 29 weeks without an appointment, the longest vacancy streak Ra has tracked. The panel's oral presentation deadline and the close of public comments on banning large-scale compounding of weight-loss drugs like Ozempic (called GLP-1s) both fall on June 29–30, creating a two-day window where the compounding industry's attention will be maximally split.

The government's new weight-loss drug program for seniors launches in 16 days, and Medicare has confirmed that no signup is required — eligible patients simply fill a prescription starting July 1. The $50-per-month access covers Wegovy, Foundayo, and the Zepbound pen. The bottleneck is Humana, which will process every prior authorization through a single national center.

Nature — the world's most prestigious science journal — published a feature this week asking whether the peptide craze is backed by real evidence. The fact that Nature is covering experimental drugs called peptides (short protein fragments used for recovery and longevity) as a cultural phenomenon signals they have crossed from biohacker niche to mainstream scientific debate. Search interest for "peptide therapy" grew 281% on Google, 459% on TikTok, and 412% on Instagram over the past year.

Quiet day. The FDA's advisory panel on experimental drugs called peptides (short protein fragments used for recovery and longevity) still has only 3 of 12 seats filled — 27 weeks without an appointment. The deadline for oral presentations at the July 23 meeting is 17 days away.

Quiet day. The FDA's advisory panel that will decide whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be made at specialty pharmacies still has only 3 of 12 seats filled — 27 weeks now without a single new appointment. The oral presentation deadline for that July 23 meeting is 18 days away; if seats remain empty, three career scientists will decide the fate of seven peptides alone.

The Department of Justice is stepping up criminal prosecution of sellers dealing in experimental drugs called peptides (short protein fragments used for recovery and longevity). A Utah doctor was indicted in April for selling unapproved peptides to over 200 patients. One of the country's largest specialty compounding pharmacies, Tailor Made Compounding, was forced to forfeit $1.79 million. Two more companies face charges or have pleaded guilty.

Quiet day. CVS, the largest pharmacy benefit manager in America, started covering Eli Lilly's new weight-loss pill Foundayo on June 1 and will add Zepbound (the injectable) by October. This puts Lilly on even footing with Novo Nordisk — maker of Wegovy and Ozempic — across every major drug plan. It matters because broader insurance coverage for branded weight-loss drugs reinforces the economics The Compound's referral business runs on.

The US government published the paperwork doctors need to prescribe weight-loss drugs like Ozempic (called GLP-1s) through Medicare's new $50-a-month program launching July 1. The form narrows eligibility: patients must have sleep apnea, liver disease, diabetes, or heart disease — not just obesity. This was the missing piece pharmacies were waiting for, and its arrival 22 days before launch improves enrollment readiness. Barque nudged its estimate that fewer than one million seniors will enroll this year.

A new player entered the peptide telehealth market this week. OneTwenty, a DTC wellness platform, launched in June with a $499 membership that bundles lab panels, wearable data, AI coaching, and telehealth visits — plus access to compounded peptides through a pharmacy network. They are positioning to carry peptides "the moment the FDA's July review clears them." It is the first company besides Hims & Hers to build commercial infrastructure at scale around the assumption that the FDA's peptide advisory panel will vote favorably on July 23.

The American Diabetes Association conference ended this weekend with landmark data for Lilly's retatrutide, a triple-action weight-loss injection. Patients on the highest dose lost an average of 70 pounds — about 28% of body weight — over 80 weeks. More striking: it is the first weight-loss drug to show meaningful relief from knee arthritis pain (73% reduction) and sleep apnea (61% improvement) in pivotal trials. Lilly plans to file for FDA approval later this year.

Lilly's retatrutide, a triple-action weight-loss injection, takes the stage at the American Diabetes Association conference this afternoon. In trial results already shared, patients on the highest dose lost an average of 70 pounds — about 28% of their body weight — over 80 weeks, the most of any drug in this class. Meanwhile, the Lancet published the first head-to-head comparison of Lilly's weight-loss pill Foundayo against Novo Nordisk's rival pill: Foundayo produced 74% more weight loss, but twice as many patients quit due to side effects.

The American Diabetes Association's annual conference opens today in New Orleans. Over the next three days, Eli Lilly will show that its pill Foundayo outperformed Novo Nordisk's rival pill in a year-long study, and present full data from retatrutide — a triple-action injection where patients lost 30% of their body weight, rivaling surgery. Novo Nordisk will debut results from CagriSema, a combination injection expected to seek U.S. approval this fall. Boehringer Ingelheim enters the race too: its injection survodutide showed nearly 17% weight loss.

The big week for weight-loss drug data is here: the American Diabetes Association's annual conference starts tomorrow in New Orleans. Eli Lilly will show that its pill Foundayo beat Novo Nordisk's rival pill in a year-long head-to-head study, and that its triple-action injection retatrutide shrank trial patients by nearly a third of their body weight — approaching bariatric surgery territory.

The American Diabetes Association's biggest annual conference opens Thursday in New Orleans, and it's loaded with weight-loss drug data. Eli Lilly will show its pill Foundayo beat Novo Nordisk's rival pill by a wide margin over a year. Lilly will also present full results for retatrutide, a triple-action injection that shrank trial patients by 30% of their body weight — approaching what surgery achieves. Novo Nordisk is countering with first human data from its REIMAGINE trials on CagriSema, a next-generation combination injection.

Quiet Tuesday — all forecasts held. This week's signal: Eli Lilly presents new data at a major diabetes conference (June 5–8) showing its weight-loss pill Foundayo beat Novo Nordisk's rival pill head-to-head over a year. That could reignite a prescription ramp that may be stalling — two Wall Street firms disagree on Foundayo's seventh-week numbers, with one reporting a drop and the other saying roughly flat.

Quiet Monday. The one move: Medicare's new $50-a-month weight-loss drug program (the "Bridge") launches July 1, but thirty days out, the government still hasn't published the operational instructions pharmacies need to fill prescriptions — no prior authorization forms, no claims-processing details. That absence at the thirty-day mark was a trigger Barque set weeks ago: if no guidance by today, nudge our low-enrollment probability up. Done — 72% to 75%.

Saturday holding pattern. Tomorrow is the day Barque committed to reassess the Medicare Bridge forecast: the government promised pharmacy instructions for its $50-a-month weight-loss drug program (launching July 1), and thirty-one days out, those instructions still haven't appeared. If they don't land by end of day Sunday, the probability that fewer than a million people sign up in the first six months ticks up from 72% to 75%. Elsewhere: the FDA's peptide advisory panel still has only three of twelve seats filled — twenty-three weeks of zero appointments — and meets in fifty-three days. Hims & Hers' peptide factory is running, but no launch announcement has followed last week's Washington Post factory tour. The weight-loss drug pipeline keeps stacking: Lilly's retatrutide showed 30.3% weight loss in a major trial, and Novo Nordisk's CagriSema faces an FDA decision around October. Quiet day; eyes on tomorrow.

Friday edition. A court ruling from March that Barque missed until today adds new context to the peptide panel story. Back in March, a federal judge blocked the health secretary's appointments to a different advisory committee — the vaccine panel — because the appointees lacked relevant expertise. The ruling sets a legal precedent: any future batch-appointment to the FDA's peptide advisory panel could face a similar challenge if the new members aren't qualified pharmacologists. That panel still has six of its twelve seats empty, twenty-three weeks and counting. Medicare's new $50-a-month program for weight-loss drugs like Ozempic (called GLP-1s) launches in thirty-two days; the promised pharmacy instructions still haven't appeared. If they're not out by Sunday, Barque upgrades the slow-enrollment forecast. Hims confirmed on its May 11 earnings call that the peptide product line is still on track for 2026. Everywhere else: holding.

Thursday edition. Quiet day across all seven pending forecasts. The FDA's peptide advisory panel still has six of twelve seats empty — twenty-two weeks and counting without a single appointment from the health secretary's office. That panel meets in fifty-five days to decide whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be legally made at specialty pharmacies. Meanwhile, Medicare's new $50-a-month program to help seniors afford weight-loss drugs like Ozempic (called GLP-1s) launches in thirty-three days, and the agency still has not published the pharmacy claims-processing instructions it promised for spring. If those instructions don't land by Sunday, Barque upgrades its forecast that enrollment will be slow. The first-ever cat weight-loss drug trial results remain expected within weeks. Everywhere else: holding.

Wednesday edition. Quiet day. Eli Lilly published a second set of results from its retatrutide program — a next-generation weight-loss drug even more powerful than Ozempic. This study focused on patients with knee arthritis, who lost an average of 71 pounds while getting substantial pain relief. That deepens the pipeline of branded weight-loss drugs like Ozempic (called GLP-1s), making the market harder for experimental drugs called peptides (short protein fragments used for recovery and longevity) to compete in. Results from the first-ever cat weight-loss drug trial are now expected within weeks. Everywhere else: the FDA's peptide advisory panel still has six of twelve seats empty at twenty-two weeks, Medicare's new $50-a-month weight-loss drug program launches in thirty-four days without promised pharmacy guidance, and Hims & Hers remains silent on peptide launch timing.

Tuesday edition. The Washington Post published a profile of Hims & Hers CEO Andrew Dudum on Saturday, describing a reporter's visit inside the company's peptide manufacturing facility in Silicon Valley — the first mainstream media tour of the plant where Hims plans to make wellness peptides. The article frames Hims's next chapter as "wellness and longevity," with experimental drugs called peptides (short protein fragments used for recovery and longevity) at the center. That nudges the probability of a public launch by year-end from 84% to 85%. Everywhere else: quiet. The FDA's peptide advisory panel still has six of twelve seats empty after twenty-one weeks. Medicare's new $50-a-month weight-loss drug program launches in thirty-five days without the pharmacy guidance the government promised this spring. GLP-1 Picks posted a single $400 conversion after three weeks of zero revenue — a sign of life, not recovery.

Monday edition. All seven tracked forecasts hold. The FDA's peptide advisory panel meets in 58 days with its six empty seats still unfilled after twenty weeks. The telehealth company Hims & Hers has been silent on its expected peptide product launch for fifteen days since reporting a $92 million quarterly loss. Medicare's new $50-a-month weight-loss drug program launches in 36 days; the government agency running it still has not published the operational guidance pharmacies need to fill prescriptions. Meanwhile, The Compound's main comparison site, GLP-1 Picks, has now gone four consecutive weeks with zero affiliate revenue and declining search visibility — the steepest sustained decline since launch. Diagnosing whether this is algorithmic, seasonal, or competitive is the top operational priority.

Saturday edition. All seven tracked forecasts hold — a genuinely quiet day. The FDA's peptide advisory panel meets in 60 days; all six empty committee seats remain unfilled after twenty weeks. Hims & Hers (the telehealth company expected to launch a peptide product line this year) has said nothing about timing thirteen days after reporting a $92 million quarterly loss. The Medicare weight-loss drug program has 38 days until its July 1 launch with no final operational guidance published. In the background, the estrogen-patch shortage driving women to telehealth hormone providers keeps worsening — one platform reports patch sales up 150% since the FDA removed its longstanding safety warning in November. HRT prescriptions have roughly doubled since 2023. That demand surge validates The Compound's decision to ship HRT Picks twelve days ago.

Quiet day across the protocol. The FDA's peptide advisory panel is 61 days out with all six empty seats still unfilled — nineteen weeks and counting since Health Secretary Kennedy committed to filling them. Hims & Hers (the telehealth company expected to launch a peptide product line this year) remains silent twelve days after quarterly earnings. The Medicare weight-loss drug program launching July 1 still has no final operational guidance at 39 days out. The biggest commercial data point: Eli Lilly's new oral weight-loss pill Foundayo hit roughly 17,000 prescriptions in its sixth week on the market, a 66% jump from the prior week and the fastest acceleration since launch — likely driven by insurance formulary activation. Meanwhile, GLP-1 Picks logged zero affiliate revenue for a third consecutive week of decline, with search positions sliding from 13 to 25. Everything else holds.

Eli Lilly's next-generation weight-loss drug retatrutide posted the strongest results ever seen in a clinical trial — people on the highest dose lost an average of 70 pounds (30% of their body weight) over 80 weeks, surpassing every existing option including weight-loss surgery equivalents. But the results came with a catch: a new side effect called dysesthesia — a persistent skin tingling and tenderness — appeared in one in five patients at the highest dose. This has never been seen with Ozempic, Wegovy, or Zepbound, and could complicate the drug's path to market. An approval filing is expected later this year. Meanwhile, the FDA panel reviewing whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be made at specialty pharmacies is still 62 days out, and all six empty seats remain unfilled. Everything else holds.

The FDA's peptide advisory panel (called PCAC) meets in 63 days, and a procedural problem is getting harder to ignore: only four of twelve authorized seats are filled, with no chairperson. Legal analysts now openly question whether the panel has enough members to formally vote. Health Secretary Kennedy, who publicly committed to making peptides more accessible, has not appointed anyone to the panel in nineteen weeks. If he doesn't act before July, the meeting could become an informal hearing that can't issue a recommendation — effectively a delay. If he batch-appoints new members in June, history suggests they'll share his pro-access stance, which could push the outcome in the opposite direction. Both scenarios are live. Hims & Hers (HIMS) remains silent on peptide timing. The Medicare weight-loss drug program launches in 41 days. Everything else holds.

Quiet Tuesday. All eight forecasts hold. The most interesting signal today isn't in the forecast log — it's in the drug pipeline. Eli Lilly's pivotal trial for retatrutide, a next-generation weight-loss drug that produced 28.7% body-weight loss in earlier studies (the best of any drug in its class), is expected to report top-line results imminently. Positive results would confirm that the weight-loss drug boom has years of pipeline ahead of it — relevant for Medicare's new $50-copay program launching July 1, for companies like Hims & Hers (HIMS) building in the space, and for The Compound's positioning. Meanwhile, the FDA's peptide advisory panel meets in 64 days, and the one move that would shift the odds — Health Secretary Kennedy filling the panel's six empty seats — has shown zero progress in eighteen weeks. No new safety incidents in the peptide world. No new enrollment data for the Medicare Bridge. A day for watching, not moving.

A quiet Monday. Three signals worth noting. First, a third major law firm — Foley & Lardner — published guidance for its clients about the FDA's upcoming July 23 advisory panel meeting on experimental drugs called peptides (short protein fragments used for recovery and longevity). When corporate lawyers start briefing clients, the stakes are real — but there are still zero new panel appointments after 18 weeks. Second, Akston Biosciences, the company testing a weekly weight-loss injection for overweight cats at Cornell, filed an amended stock-offering document with the SEC — a sign its IPO is advancing, and the amendment may contain trial data. Third, a US veterans' study found users of weight-loss drugs like Ozempic (called GLP-1s) had a 35% higher risk of a rare eye condition — early lawsuit fuel, not a crisis. All seven forecasts hold.

A quiet Sunday on regulatory news, but the pipeline is crowding. Eli Lilly's next-generation weight-loss drug retatrutide posted the strongest clinical result yet — patients lost nearly 29% of their body weight in a late-stage trial, outperforming every drug in the category including Ozempic and Zepbound. No filing date yet, but this is the competitive threat the branded weight-loss drug market must absorb. Medicare's weight-loss drug program launches July 1 — 44 days away — and ABC News is now covering the $50-per-month copay, the latest in a growing wave of mainstream attention. The estrogen patch shortage may last up to three years per manufacturers, validating the long runway for menopause telehealth. The FDA's peptide advisory panel still shows zero new appointments 66 days before the July 23 meeting.

A quiet weekend on hard regulatory news but a loud one on cultural and institutional signal. ProPublica — top-tier investigative — published a feature this week framing the FDA's peptide reversal as opening the market to unsafe drugs. That is the first tier-1 institutional safety pushback into the PCAC July 23 window, and it adds weight to our long-running "peptide safety incident makes a top-5 outlet" forecast. Meanwhile peptide search volume surpassed "Ozempic" on US Google Trends per TechBuzz/eMarketer syndication — a quantified Kardashian-Met-Gala-class cultural inflection saying consumer demand for peptides now outruns the prior wave. Hims & Hers continues to not announce a peptide product despite the demand pull and the $300B peptide wellness market forecast published May 12 — the silence becomes more anomalous each week. Medicare's GLP-1 Bridge is now 45 days from launch with NPR's May 6 explainer driving mainstream awareness and Humana confirmed as the central processor via LI NET infrastructure; operational rails are hardening but eligibility is narrowing (Zepbound vial and single-dose pen formulations remain excluded). The PCAC roster shows zero new appointments 67 days before the meeting.

Quiet Saturday on the regulatory front, but a meaningful shift in how peptide harms might first surface publicly: researchers are now using AI to scan 400,000 Reddit posts for overlooked GLP-1 side effects — the same methodology applied to compounded peptides would shorten the path from anonymous user complaint to publishable adverse-event report. Medicare's GLP-1 Bridge continues to harden its operational rails 46 days before launch, with pharmacies confirmed to need no opt-in and a dedicated CMS BIN/PCN routing now live. Hims & Hers still has not announced a peptide DTC product despite 281% YoY Google growth and 459% TikTok growth for "peptide therapy." The PCAC roster shows no new appointments 68 days before the July 23 hearing on BPC-157, KPV, TB-500, and MOTs-C. One operator-side note: yesterday's clarification effectively resolved the Compound portfolio-ship forecast in the affirmative and that flag is now waiting for formal resolution.

Quiet day. All seven Barque forecasts held steady. The strongest signal came from women's health: nationwide shortages of estrogen patches — used by women going through menopause for hormone therapy — are intensifying. Prescriptions have nearly tripled since 2018 after the FDA removed a long-standing safety warning last November, and manufacturers say the shortage could drag on for three years. Telehealth platforms specializing in hormone prescriptions report sales up 150%. Meanwhile, Eli Lilly's Foundayo weight-loss pill held steady at over 7,000 weekly prescriptions in its fourth week, with nearly half of orders coming through Lilly's direct-to-patient channel. No new safety incidents involving experimental drugs called peptides (short protein fragments used for recovery and longevity). The FDA's advisory panel meeting on peptides remains 69 days away with no changes to the agenda or committee roster.

Quiet day. Novo Nordisk presented new data at Europe's largest obesity conference showing its next-generation combination drug CagriSema preserved patients' muscle mass during weight loss — addressing the main knock on current weight-loss drugs like Ozempic (called GLP-1s), which can strip away muscle alongside fat. Novo has filed for FDA approval and expects a decision by Q4 this year. Separately, ECRI and the Institute for Safe Medication Practices — two respected patient-safety watchdogs — warned that most experimental drugs called peptides (short protein fragments used for recovery and longevity) lack reliable safety data, escalating the concern from blog-level to institutional alarm. Six of seven Barque forecasts held steady; the peptide safety forecast edged up slightly.

Quiet day. Novo Nordisk issued a press release marketing Wegovy's inclusion in Medicare's new $50-a-month weight-loss drug program, which launches July 1 — the first drug maker actively promoting the program ahead of opening day. Meanwhile, the shortage of estrogen patches for menopause is worsening: roughly twice as many women now use hormone therapy as three years ago, and telehealth platforms report patch sales up 150% since November. The FDA says there is no official shortage, adding to patient frustration. On the experimental drug front, the FDA's peptide advisory panel is now confirmed as a two-day meeting (July 23–24), covering seven peptides instead of the originally tracked four. All seven Barque forecasts held steady today.

Hims & Hers reported Q1 earnings last night: a $92 million net loss on $608 million in revenue, swinging from a $50 million profit a year ago. Restructuring costs from its pivot to branded weight-loss drugs like Ozempic (called GLP-1s) drove the loss. On whether Hims launches a line of experimental drugs called peptides (short protein fragments used for recovery and longevity) by year-end: management confirmed preparations are underway and they're watching the FDA's peptide advisory panel in July, but said they "likely will not be first to market." That pushes timing risk into the back half of 2026 and nudges launch probability to 84%.

Hims & Hers reports Q1 earnings tonight — the company that acquired a peptide manufacturing facility in California fourteen months ago finally faces analysts expecting an 85% profit drop. What management says about when (not whether) it launches its line of experimental drugs called peptides (short protein fragments used for recovery and longevity) will move the most-watched forecast in this log. Results land after market close; tomorrow's brief will incorporate them.

Quiet day before a busy one. All seven forecasts held.

Two small but real moves today, both in the same direction Barque has been leaning.

Quiet day. Hims & Hers, the telehealth company that bought a peptide manufacturing facility 14 months ago, reports first-quarter earnings on Sunday. Wall Street has cut its profit estimates by nearly 80% since February, and the call will be the first real test of whether management puts a concrete date on selling experimental drugs called peptides (short protein fragments used for recovery and longevity) directly to consumers. The FDA's peptide advisory panel has only four members — well under its normal roster — with 76 days until it decides whether specialty pharmacies can legally make these drugs. And the US Medicare agency still hasn't published the doctor-facing rulebook for its new $50 weight-loss-drug program for seniors, now 54 days from launch.

Mostly quiet Wednesday. NPR yesterday published a consumer explainer for the Medicare weight-loss drug program launching July 1 — a $50-per-month copay for drugs like Ozempic, Wegovy, and a new pill called Foundayo that normally cost over $1,000. The catch: the program requires prior authorization and routes through a centralized processor rather than normal pharmacies. Those friction points may keep early enrollment below expectations.

Quiet Tuesday. All seven forecasts holding. The most notable signal sitting outside the active forecast set: Novo Nordisk (the maker of Ozempic and Wegovy) filed for FDA approval of CagriSema — a next-generation combination weight-loss drug that achieved 22.7% body weight loss in its main trial, nearly 50% more effective than Wegovy alone. An FDA decision is expected around October. If approved, it reshapes the competitive landscape for every weight-loss product The Compound covers.

Quiet Monday. The FDA's peptide advisory panel still has six empty seats after eleven weeks — no new appointments over the weekend. The panel meets July 23 to decide whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be legally custom-made at specialty pharmacies. One detail confirmed today: the panel will evaluate each peptide individually and can attach conditions like purity standards and prescribing limits, rather than issuing a simple yes-or-no.

The FDA's peptide advisory panel was formally renewed this week for two more years, but Health Secretary Kennedy still hasn't filled any of its six empty seats in eleven weeks. Experimental drugs called peptides — short protein fragments used for recovery and longevity — are at the center of a July decision about whether they can be legally custom-made at specialty pharmacies. A three-person panel reviewing seven of them over two days is more likely to defer than act boldly.

Quiet day. None of the seven forecasts Barque tracks moved.

The FDA proposed a rule to permanently bar large-scale compounding pharmacies from making copycat versions of weight-loss drugs like Ozempic (called GLP-1s). The proposal covers semaglutide, tirzepatide (the ingredient in Zepbound), and liraglutide. Public comments are open through June 29. This is separate from the July 23 panel meeting about peptides (experimental drugs used for recovery and longevity) — different drugs, different regulatory pathway.

The government panel that will decide whether experimental drugs called peptides (short protein fragments used for recovery and longevity) can be made at specialty pharmacies has only 3 of its 12 voting seats filled — and no chair. Health Secretary Kennedy has been filling similar vacancies on other advisory boards, including the vaccine committee back in February, but hasn't touched this one in nine weeks. That panel meets July 23 to decide the fate of BPC-157 and six other peptides. The fewer independent voices in the room, the harder the outcome is to predict.

The biggest thing Barque missed this month: back in November, the US government quietly removed its strongest safety warnings from hormone replacement therapy — the medications millions of women use for menopause symptoms. Since then, prescriptions have roughly doubled. Demand for estrogen patches has surged 184% since 2023. The country is now running short, with one major patch brand in nationwide shortage and supply potentially tight for years.

Quiet Tuesday — none of the eight live forecasts moved.

Eli Lilly's new weight-loss pill Foundayo filled just 3,707 prescriptions in its second week on the market — compared with about 18,400 for Novo Nordisk's rival pill, oral Wegovy, in the same period. Lilly's stock fell on the data. For anyone watching the weight-loss drug race, Novo is winning the oral pill battle so far, even though Foundayo can be taken any time of day without fasting.

A week of confirmation rather than surprise. Hims & Hers confirmed that the peptide manufacturing facility it bought in California last February is now operating and doing active research — its stock jumped 49% in five days. A launch of recovery and longevity products through its telehealth platform this year looks increasingly likely, though an upcoming earnings report on May 11 will test whether the rally is built on revenue or hope.

The US Medicare agency quietly delayed part of a program meant to expand access to weight-loss drugs like Ozempic (called GLP-1s) for people on government insurance. The delay, reported this week, hints that the plumbing behind Medicare's $50-per-month GLP-1 program for seniors — set to launch July 1 — may be harder to build than the policy itself. That makes it more likely the program starts slowly, which is what Barque already expects.

Quiet day across most of our tracked domains. The FDA's advisory meeting on experimental drugs called peptides (short protein fragments used for recovery and longevity) is now 89 days away — July 23–24 — and a public comment window opens soon for anyone wanting to make their case to the panel.

Eli Lilly's weight-loss pill Foundayo — the first oral competitor to Novo Nordisk's Wegovy pill — has been shipping from US pharmacies since April 6. Both are priced at $149 a month without insurance.

Quiet day. The main story we're watching — whether the FDA will loosen its rules this summer on a group of experimental drugs called peptides (things like BPC-157, used for recovery and longevity) — is waiting on two catalysts: a July meeting of the FDA's peptide advisory panel, and a May 11 earnings call from the telehealth company Hims & Hers, which is expected to lay out its own peptide product plans. Nothing has moved our odds since yesterday.

PCAC committee composition is the structural variable, not the evidence. The morning run focused on evidence (safety dossiers, political statements, stock moves). The afternoon signal harvest surfaced the mechanism: PCAC has 6 vacancies including the chair, and Kennedy controls appointments. This is a structural factor that supersedes the scientific debate. When you control who sits on the panel, the panel's recommendation is downstream of appointments, not evidence. Heuristic: in any advisory-committee forecast, check vacancy count and appointment authority before analyzing the evidence the committee will review.

New heuristic promoted. "Incumbent acquires facility 12+ months before the policy window opens" is a reusable signal pattern. Hims acquired its California peptide facility Feb 2025 — fourteen months before the April 22 2026 Category 2 reclassification. Same structural class as Novo's 2021 Kalundborg expansion preceding Wegovy mainstreaming by 18 months. "Pre-positioning-by-M&A" added to the reference class for regulatory-adjacent forecasts.